Tuberculosis in household contacts of multidrug-resistant tuberculosis patients

International Journal of Tuberculosis and Lung Disease

Volumn 15, Issue 9, 2011, Pages 1164-1169

  Grandjean, Louis ^a,b   Crossa, A ^c,d   Gilman, R H ^b,e,f   Herrera, C ^c   Bonilla, C ^c   Jave, O ^c   Cabrera, J L ^g   Martin, L ^b   Escombe, A R ^h   Moore, D A J ^b,h  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSIDAD PERUANA CAYETANO HEREDIA   (Peru)

^c Unidad Tecnica TB MDR   (Peru)

^d PARTNERS IN HEALTH   (United States)

^e JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^f ASOCIACIÓN BENÉFICA PRISMA   (Peru)

^g HOSPITAL NACIONAL DANIEL ALCIDES CARRIÓN   (Peru)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Household contacts; Incidence; Multidrug resistant; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; ASTHMA; BACTERIAL TRANSMISSION; CHILD; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; CONTACT EXAMINATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HOUSEHOLD; HUMAN; INCIDENCE; INFANT; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; PERU; PHENOTYPE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE; SPUTUM CULTURE; SPUTUM SMEAR; SURVIVAL RATE; TUBERCULOSIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; COHORT STUDIES; COST OF ILLNESS; FAMILY CHARACTERISTICS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MICROBIAL SENSITIVITY TESTS; MULTIVARIATE ANALYSIS; PERU; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 80051696220     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.11.0030     Document Type: Article

References (22)

1. World Health Organization. Anti-tuberculosis drug resistance in the world. Report no. 4. WHO/HTM/TB/2008.394. Geneva, Switzerland: WHO, 2008.
2. Schaaf H S. Drug-resistant tuberculosis in children. S Afr Med J 2007; 97: 995-997. (Pubitemid 350027957)
3. Sneag D B, Schaaf H S, Cotton M F, Zar H J. Failure of chemoprophylaxis with standard antituberculosis agents in child contacts of MDR-TB cases. Pediatr Infect Dis J 2007; 26: 1142-1146. (Pubitemid 350190948)
4. Escombe A R, Moore D A, Gilman R H, et al. Upper-room ultraviolet light and negative air ionization to prevent tuberculosis transmission. PLoS Med 2009; 6: e43.
5. Martineau A R, Timms P M, Bothamley G H, et al. High-dose vitamin D(3) during intensive-phase antimicrobial treatment of pulmonary tuberculosis: a double-blind randomised controlled trial. Lancet 2011; 377: 189-190.
6. Shin S, Furin J, Bayona J, Mate K, Kim J Y, Farmer P. Community-based treatment of MDR-TB in Lima, Peru: 7 years of experience. Soc Sci Med 2004; 59: 1529-1539. (Pubitemid 38891418)
7. Caceres C F, Mendoza W. The national response to the HIV/ AIDS epidemic in Peru: accomplishments and gaps-a review. J Acquir Immune Defi c Syndr 2009; 51 (Suppl 1): S60-S66.
8. Morrison J, Pai M, Hopewell P C. Tuberculosis and latent tuberculosis infection in close contacts of people with pulmonary tuberculosis in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Infect Dis 2008; 8: 359-368.
9. Snider D E Jr, Kelly G D, Cauthen G M, Thompson N J, Kilburn J O. Infection and disease among contacts of tuberculosis cases with drug-resistant and drug-susceptible bacilli. Am Rev Respir Dis 1985; 132: 125-132. (Pubitemid 15026199)
10. Mehta J, Diaz C, Guha B, Harvill L, Krishnaswamy G. Appearance of drug-resistant tuberculosis in rural Tennessee. South Med J 1995; 88: 60-64.
11. Reichler M R, Reves R, Bur S, et al. Evaluation of investigations conducted to detect and prevent transmission of tuberculosis. JAMA 2002; 287: 991-995. (Pubitemid 34252056)
12. Bayona J, Chavez-Pachas A M, Palacios E, Llaro K, Sapag R, Becerra M C. Contact investigations as a means of detection and timely treatment of persons with infectious MDR-TB. Int J Tuberc Lung Dis 2003; 7 (Suppl 3): S501-S509. (Pubitemid 38004731)
13. Ministerio de Salud Peru. Norma técnica de salud para el control de la tuberculosis. 1ra edición. Lima, Peru: Ministerio de Salud, 2006. [Spanish]
14. Fox W, Ellard G A, Mitchison D A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis 1999; 3 (Suppl 2): S231-S279. (Pubitemid 29481843)
15. van Soolingen D, Borgdorff M W, de Haas P E, et al. Molecular epidemiology of tuberculosis in the Netherlands: a nationwide study from 1993 through 1997. J Infect Dis 1999; 180: 726-736. (Pubitemid 29411359)
16. Nitta A T, Knowles L S, Kim J, et al. Limited transmission of MDR-TB despite a high proportion of infectious cases in Los Angeles County, California. Am J Respir Crit Care Med 2002; 165: 812-817. (Pubitemid 34229652)
17. Andersson D I, Hughes D. Antibiotic resistance and its cost: is it possible to reverse resistance? Nat Rev Microbiol 2010; 8: 260-271.
18. Vazquez-Gallardo R, Anibarro L, Fernandez-Villar A, et al. MDR-TB in a low-incidence region shows a high rate of transmission. Int J Tuberc Lung Dis 2007; 11: 429-435. (Pubitemid 46595774)
19. Borrell S, Gagneux S. Infectiousness, reproductive fi tness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009; 13: 1456-1466.
20. Blower S M, McLean A R, Porco T C, et al. The intrinsic transmission dynamics of tuberculosis epidemics. Nat Med 1995; 1: 815-821.
21. Verver S, Warren R M, Beyers N, et al. Rate of re-infection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med 2005; 171: 1430-1435. (Pubitemid 40800517)
22. Suarez-Garcia I, Rodriguez-Blanco A, Vidal-Perez J L, et al. Risk factors for MDR-TB in a tuberculosis unit in Madrid, Spain. Eur J Clin Microbiol Infect Dis 2009; 28: 325-330.